In GC, prior reports found no significant difference between the recurrence-free survival (RFS) based on assessment of total FAK; however, the RFS of patients in the positive pFAK group was found to be shorter than the patients whose tumors lack pFAK (13). The gene discussed is PTK2; the disease is gastric cancer.